title: [Intermediate dose of Ara-C (IDAra-C) for the treatment of refractory and relapsed lymphoid malignancies].
authors.forename: S
authors.initials: S
authors.lastname: Taniguchi
authors.forename: T
authors.initials: T
authors.lastname: Shibuya
authors.forename: E
authors.initials: E
authors.lastname: Morioka
authors.forename: N
authors.initials: N
authors.lastname: Ohhara
authors.forename: T
authors.initials: T
authors.lastname: Ohtsuka
authors.forename: Y
authors.initials: Y
authors.lastname: Hirota
authors.forename: Y
authors.initials: Y
authors.lastname: Yamano
authors.forename: K
authors.initials: K
authors.lastname: Miki
authors.forename: Y
authors.initials: Y
authors.lastname: Asano
authors.forename: Y
authors.initials: Y
authors.lastname: Niho
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D015459:Leukemia-Lymphoma, Adult T-Cell / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
chemical_list: D003561:Cytarabine